Trial · NCT02860676
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
NCT02860676, Phase 1, Completed, University of California, San Diego; results first posted 2025-12-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961. Trials, record NCT02860676. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02860676
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
- NCT number
- NCT02860676
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- cirmtuzumab
- First posted
- 2016-08-09
- Last updated
- 2025-12-15
- Results first posted
- 2025-12-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | From start of investigational treatment to discontinuation from trial participation, on average 159 days | Adverse events (AE) assessed by CTCAE v4.0 during cirmtuzumab treatment and during 3 months of follow-up |
| Secondary | Overall Response Rate | From start of investigational treatment to discontinuation from trial participation, on average 159 days | Overall response rate by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria following 6 months of biweekly dosing of cirmtuzumab |
| Secondary | Progression Free Survival (PFS) | From start of investigational treatment to tumor progression or death, on average 16.66 months | The duration of time from the start of study treatment until objective tumor progression or death determined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria |
| Secondary | Stable Disease Rate (SD) | From start of investigational treatment to discontinuation from trial participation, on average 159 days | The Stable Disease Rate based on number of subjects who have absence of disease progression as determined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. |
| Secondary | Partial Response Rate (PR) | From start of investigational treatment to discontinuation from trial participation, on average 159 days | The percentage of subjects who achieve partial clinical response determined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. |
| Secondary | Undetectable Minimal Residual Disease (uMRD) Rate | From start of investigational treatment to discontinuation from trial participation, on average 159 days | The Undetectable Minimal Residual Disease rate based on the number of subjects achieving undetectable minimal residual disease as determined by International Workshop on Chronic Lymphocytic Leukemia (iWCLL) criteria. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | From start of investigational treatment to discontinuation from trial participation, on average 159 days | Adverse Events | NUMBER | |
| SECONDARY | Overall Response Rate | From start of investigational treatment to discontinuation from trial participation, on average 159 days | percentage of participants | NUMBER | |
| SECONDARY | Progression Free Survival (PFS) | From start of investigational treatment to tumor progression or death, on average 16.66 months | Only one subject progressed after being on study at 16.66 months. The other two subjects did not progress but went off study at months 3.84 and 1.26, respectively; thus, their PFS status was censored at off study date. | months | MEAN |
| SECONDARY | Stable Disease Rate (SD) | From start of investigational treatment to discontinuation from trial participation, on average 159 days | percentage of participants | NUMBER | |
| SECONDARY | Partial Response Rate (PR) | From start of investigational treatment to discontinuation from trial participation, on average 159 days | All 3 patients has stable disease while on treatment. Partial response rate is therefore 0%. | percentage of participants | NUMBER |
| SECONDARY | Undetectable Minimal Residual Disease (uMRD) Rate | From start of investigational treatment to discontinuation from trial participation, on average 159 days | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 1 Adverse Events | Eye disorders | 1 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 2 Adverse Events | Eye disorders | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 3 Adverse Events | Eye disorders | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 4 Adverse Events | Eye disorders | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 1 Adverse Events | Abdominal pain | 1 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 2 Adverse Events | Abdominal pain | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 3 Adverse Events | Abdominal pain | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 4 Adverse Events | Abdominal pain | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 1 Adverse Events | Constipation | 0 | Adverse Events | |
| Number of Treatment-emergent Adverse Events as Assessed by CTCAE v4.0 | Grade 2 Adverse Events | Constipation | 1 | Adverse Events |
1 to 10 of 45Source ClinicalTrials.gov
See all 45 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cirmtuzumab | 3 | |
| Overall Study | COMPLETED | Cirmtuzumab | 2 | |
| Overall Study | NOT COMPLETED | Cirmtuzumab | 1 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye disorders, other | Eye disorders | Cirmtuzumab | 1 | 3 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Cirmtuzumab | 1 | 3 | 1 |
| other | Constipation | Gastrointestinal disorders | Cirmtuzumab | 1 | 3 | 1 |
| other | Gastrointestinal disorders, other | Gastrointestinal disorders | Cirmtuzumab | 1 | 3 | 1 |
| other | Dizziness | General disorders | Cirmtuzumab | 1 | 3 | 2 |
| other | Upper respiratory infection | Infections and infestations | Cirmtuzumab | 1 | 3 | 1 |
| other | Anemia | Investigations | Cirmtuzumab | 3 | 3 | 6 |
| other | Thrombocytopenia | Investigations | Cirmtuzumab | 3 | 3 | 7 |
| other | Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Cirmtuzumab | 1 | 3 | 1 |
| other | Skin and subcutaneous tissue disorders, other | Skin and subcutaneous tissue disorders | Cirmtuzumab | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cirmtuzumab | 0 | 3 |
| Total, other adverse events | Cirmtuzumab | 3 | 3 |
| Total, serious adverse events | Cirmtuzumab | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29859176 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02860676
GET https://conductscience.org/api/trials/v1/NCT02860676/results?page=2